The growing global concern about obesity and its impact on other health related matters is driving a surge in companies developing solutions.
For investors seeking thematic funds focused on the sector there are several options, but there is room for more and Amplify ETFs is the latest to launch an index-based fund offering exposure to those in what is known as GLP-1 treatments.
The firm, which has over $9 billion assets under management and acquired a suite of specialty funds last summer from ETF Managers Group, has announced the launch of the Amplify Weight Loss
Drug & Treatment ETF (NYSE: THNR).
The fund tracks the VettaFi Weight Loss Drug & Treatment Index which allocates 70% of drug manufacturers, those who are launching or testing GLP-1 treatments. The other 30% is allocated to ‘enablers’ or companies engaged in outsourced development and manufacturing, measurement and analysis, and/or distribution or administration of GLP-1 drugs.
With an estimated one billion people globally defined as obese and the World Health Organization recently reporting that the figure had doubled in the period 1990-2022, the scope for returns from those companies offering solutions is clear.
Last month, another niche ETF provider also launched a thematic fund focused on GLP-1 treatments. The renamed Tema Obesity and Cardiometabolic ETF trades on the Nasdaq with the ticker HRTS.
However, the thematic funds market has seen some pullback recently following the surge of interest in specialities such as work from home funds which gained during the pandemic. Investors have already yanked nearly $4 billion so far this year from exchange-traded funds investing in themes like clean energy and cloud computing, after withdrawing $4.6 billion from such funds as a whole in 2023, according to Bloomberg Intelligence. There is expectation that a rebound will come once investors recover from over-allocation to some themes which turned out to be ‘micro-bubbles’.
Meanwhile, Raymond James and Tritonpoint Partners separately welcomed father-son teams, including a breakaway from UBS in Missouri.
Paul Atkins has asked staff to solicit public comment on novel ETFs, pausing the clock on as many as 24 filings linked to the booming event contracts market.
From 401(k)s to retail funds, Deloitte sees private equity and credit crossing into mainstream investing on two fronts at once.
Big-name defections from Morgan Stanley, UBS, and Merrill Lynch headline a busy two weeks of recruiting for the wirehouse.
Markets have always been unpredictable. What has changed is the amount of information investors are trying to process and the growing role advisors play in helping clients avoid emotional decisions
Wellington explores how multi strategy hedge funds may enhance diversification
As technical expertise becomes increasingly commoditized, advisors who can integrate strategy, relationships, and specialized expertise into a cohesive client experience will define the next era of wealth management
